Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications
Polycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/9/1319 |
| _version_ | 1797579314574655488 |
|---|---|
| author | Mardia López-Alarcón Víctor Saúl Vital-Reyes Eduardo Almeida-Gutiérrez Jorge Maldonado-Hernández Salvador Flores-Chávez Juan Manuel Domínguez-Salgado José Vite-Bautista David Cruz-Martínez Aly S. Barradas-Vázquez Ricardo Z’Cruz-López |
| author_facet | Mardia López-Alarcón Víctor Saúl Vital-Reyes Eduardo Almeida-Gutiérrez Jorge Maldonado-Hernández Salvador Flores-Chávez Juan Manuel Domínguez-Salgado José Vite-Bautista David Cruz-Martínez Aly S. Barradas-Vázquez Ricardo Z’Cruz-López |
| author_sort | Mardia López-Alarcón |
| collection | DOAJ |
| description | Polycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without PCOS were evaluated. The clinical biomarkers of alterations related to glucose (glucose, insulin, and clamp-derived glucose disposal − <i>M</i>), liver (aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase), and endothelium (arginine, asymmetric dymethylarginine, carotid intima-media thickness, and flow-mediated dilation) metabolism were measured; participants were categorized into four groups according to their obesity (OB) and hyperandrogenemia (HA) status as follows: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were very frequent in women with PCOS (≈70%). BMI correlated with all biomarkers, whereas free testosterone (FT) correlated with only glucose- and liver-related indicators. Although insulin sensitivity and liver enzymes were associated with FT, women with obesity showed lower M (coef = 8.56 − 0.080(FT) − 3.71(Ob); <i>p</i> < 0.001) and higher aspartate aminotransferase (coef = 26.27 + 0.532 (FT) + 8.08 (Ob); <i>p</i> = 0.015) than lean women with the same level of FT. Women with obesity showed a higher risk of metabolic disorders than lean women, independent of hyperandrogenemia. Clinicians are compelled to look for metabolic alterations in women with PCOS. Obesity should be treated in all cases, but hyperandrogenemia should also be monitored in those with glucose-or liver-related disturbances. |
| first_indexed | 2024-03-10T22:34:20Z |
| format | Article |
| id | doaj.art-a036535c801c43e391e5054268c3f195 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T22:34:20Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-a036535c801c43e391e5054268c3f1952023-11-19T11:30:35ZengMDPI AGJournal of Personalized Medicine2075-44262023-08-01139131910.3390/jpm13091319Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical ImplicationsMardia López-Alarcón0Víctor Saúl Vital-Reyes1Eduardo Almeida-Gutiérrez2Jorge Maldonado-Hernández3Salvador Flores-Chávez4Juan Manuel Domínguez-Salgado5José Vite-Bautista6David Cruz-Martínez7Aly S. Barradas-Vázquez8Ricardo Z’Cruz-López9Unidad de Investigación Médica en Nutrición, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoDepartamento de Medicina Reproductiva, Hospital de Ginecología y Obstetricia, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 02990, MexicoDepartmento de Investigación y Educación en Salud, Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoUnidad de Investigación Médica en Nutrición, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoUnidad de Investigación Médica en Nutrición, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoUnidad de Investigación Médica en Nutrición, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoDepartamento de Medicina Reproductiva, Hospital de Ginecología y Obstetricia, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 02990, MexicoDepartamento de Medicina Reproductiva, Hospital de Ginecología y Obstetricia, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 02990, MexicoUnidad de Investigación Médica en Nutrición, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 06270, MexicoFacultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, MexicoPolycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without PCOS were evaluated. The clinical biomarkers of alterations related to glucose (glucose, insulin, and clamp-derived glucose disposal − <i>M</i>), liver (aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase), and endothelium (arginine, asymmetric dymethylarginine, carotid intima-media thickness, and flow-mediated dilation) metabolism were measured; participants were categorized into four groups according to their obesity (OB) and hyperandrogenemia (HA) status as follows: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were very frequent in women with PCOS (≈70%). BMI correlated with all biomarkers, whereas free testosterone (FT) correlated with only glucose- and liver-related indicators. Although insulin sensitivity and liver enzymes were associated with FT, women with obesity showed lower M (coef = 8.56 − 0.080(FT) − 3.71(Ob); <i>p</i> < 0.001) and higher aspartate aminotransferase (coef = 26.27 + 0.532 (FT) + 8.08 (Ob); <i>p</i> = 0.015) than lean women with the same level of FT. Women with obesity showed a higher risk of metabolic disorders than lean women, independent of hyperandrogenemia. Clinicians are compelled to look for metabolic alterations in women with PCOS. Obesity should be treated in all cases, but hyperandrogenemia should also be monitored in those with glucose-or liver-related disturbances.https://www.mdpi.com/2075-4426/13/9/1319polycystic ovary syndromeobesity-related metabolic disordershyperandrogenemia |
| spellingShingle | Mardia López-Alarcón Víctor Saúl Vital-Reyes Eduardo Almeida-Gutiérrez Jorge Maldonado-Hernández Salvador Flores-Chávez Juan Manuel Domínguez-Salgado José Vite-Bautista David Cruz-Martínez Aly S. Barradas-Vázquez Ricardo Z’Cruz-López Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications Journal of Personalized Medicine polycystic ovary syndrome obesity-related metabolic disorders hyperandrogenemia |
| title | Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications |
| title_full | Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications |
| title_fullStr | Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications |
| title_full_unstemmed | Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications |
| title_short | Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications |
| title_sort | obesity and hyperandrogenemia in polycystic ovary syndrome clinical implications |
| topic | polycystic ovary syndrome obesity-related metabolic disorders hyperandrogenemia |
| url | https://www.mdpi.com/2075-4426/13/9/1319 |
| work_keys_str_mv | AT mardialopezalarcon obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT victorsaulvitalreyes obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT eduardoalmeidagutierrez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT jorgemaldonadohernandez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT salvadorfloreschavez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT juanmanueldominguezsalgado obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT josevitebautista obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT davidcruzmartinez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT alysbarradasvazquez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications AT ricardozcruzlopez obesityandhyperandrogenemiainpolycysticovarysyndromeclinicalimplications |